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The oral adsorbent AST-120 has the potential to delay dialysis initiation and improve survival of patients on dialysis. We evaluated
theeﬀectofAST-120ondialysisinitiationanditspotentialtoimprovesurvivalinpatientswithchronickidneydisease.Thepresent
retrospectivepair-matchedstudyincluded560patients,groupedaccordingtowhetherornottheyreceivedAST-120beforedialysis
(AST-120 and non-AST-120 groups). The cumulative dialysis initiation free rate and survival rate were compared by the Kaplan-
Meier method. Multivariate analysis was used to determine the impact of AST-120 on dialysis initiation. Our results showed
signiﬁcant diﬀerences in the 12- and 24-month dialysis initiation free rate (P<0.001), although no signiﬁcant diﬀerence was
observed in the survival rate between the two groups. In conclusion, AST-120 delays dialysis initiation in chronic kidney disease
(CKD) patients but has no eﬀect on survival. AST-120 is an eﬀective therapy for delaying the progression of CKD.
1.Introduction
The number of dialysis patients is increasing worldwide [1]
as a consequence of treatment to prevent progression of
chronic kidney disease (CKD) remaining largely unresolved.
To prevent CKD progression from an early stage, many clin-
ical studies have suggested that disease progression may be
curbed by controlling dietary factors, blood pressure, lipids,
anemia, and mineral balance [2]. However, management
of protein and salt restriction along with blood pressure
is not always eﬀective in patients using a multidisciplinary
approach, including the use of angiotensin-converting
enzymeinhibitors(ACEIs)andangiotensinreceptorblockers
(ARBs), that forms the basic strategy currently used to
control CKD progression [1, 3]. This suggests the necessity
for further development of modalities to control CKD
progression.
AST-120 (Kremezin, Kureha Corporation, Tokyo, Japan)
is an oral adsorbent consisting of microspheres made from
porous carbon material [4]. By adsorbing uremic toxins,
including indoxyl sulfate, AST-120 can slow CKD progres-
sionanddelaydialysisinitiation.Thedrughasbeenclinically
used in Japan since 1991 and is covered by health insurance
[5, 6].
Although large-scale multicenter trials have shown the
eﬀect of AST-120 to delay dialysis initiation in CDK patients,
these reports were published in the late 1980s [7]. Updating
data on the AST-120 eﬃcacy for delaying dialysis initiation
is therefore necessary under the currently employed basic
strategy. Recently, Ueda et al. [8]a n dM a e d ae ta l .[ 9]
reported the eﬃcacy of AST-120 on CKD progression and
delay in dialysis initiation. These studies used the propensity
score matching method to compare the eﬃcacy of AST-120,
although the number of patients studied was relatively small.2 International Journal of Nephrology
The importance of early diagnosis and treatment of CKD
patientsiswellestablishedascardiovasculardiseaseisknown
to be the primary cause of high mortality in these patients.
Recently, Ueda et al. [10] reported improved prognosis in
CKD patients who had been administered AST-120 during
the predialysis period. However, further evidence is required
to elucidate the eﬀect of AST-120 on the prognosis of dialysis
patients [11].
In the present study, we performed a retrospective exam-
ination on the therapeutic eﬀect of AST-120 in combination
with current basic treatment regimens in CKD patients. To
guarantee the validity of the retrospective analysis we used
the propensity score method to identify a matched-control
group.
2. Patientsand Methods
Between January 1991 and December 2010, 872 of CKD
patients were followed until dialysis initiation at Oyokyo
Kidney Research Institute, Hirosaki. Of the 872 patients, 363
had a history of using AST-120, and 509 patients had never
receivedAST-120.Byapplyingthepropensityscorematching
method, 560 patients were pair-matched (n = 280 of each
group) and enrolled in the study. Dialysis initiation was
determined based on scores consisting of (1) clinical symp-
tom(ﬂuidretention,electrolyteabnormality,gastrointestinal
symptoms, circulatory symptoms, neurological symptoms,
hematological disorders, and vision disorders), (2) remnant
kidney function (serum creatinine or creatinine clearance),
(3) impairment level of daily living, (4) age (10 years or
less, and 65 or older), and (5) existence of systemic vascular
disorder according to the guidelines for introducing patients
to dialysis issued by the Ministry of Health, Labour and
Welfare of Japan. Patients with sum total 60 or higher
were indication for dialysis initiation (Table 1)[ 12]. This
study was approved by the institutional ethical committee of
Oyokyo Kidney Research Institute.
2.1. Pair-Matching Methods. To guarantee the validity of this
retrospective analysis, a propensity score was applied to pair-
matched patients. Propensity scores were calculated using
logistic analysis. The data used in the analyses included age,
gender, blood pressure, biochemistry, concomitant drugs
(activated vitamin-D, ACEIs, ARBs, and calcium blockers),
estimated glomerular ﬁltration rate (eGFR), presence of
diabetes mellitus, and cardiovascular disease (heart failure,
myocardial infarction and angina pectoris) at the initial
visit. The eGFR was calculated using age, gender, and serum
creatinine (sCr) by the equation shown below [13]. This
eGFR equation for Japanese patients is a modiﬁed version of
the abbreviated Modiﬁcation of Diet in Renal Disease Study
formula [14]. [eGFR mL/min/1.73m2 = 194 × sCr−1.094×
age−0.287 (×0.739, if female)]. AST-120 administration quit-
ted after the initiation of hemodialysis.
Based on the scores of each patient, two patients with a
score within 0.03 were selected as a pair. For the AST-120
group, the baseline was deﬁned as the time of initiation of
AST-120treatment.Baselineforpatientsinthecontrolgroup
was deﬁned as the date of measurement of eGFR that was
closest to the baseline eGFR level of their counterpart in the
AST-120 group.
We compared the eﬀect of AST-120 to delay dialysis
initiation in patients taking AST-120 (AST-120 group) with
pair-matched patients not taking AST-120 (non-AST-120
group). Because all patients received dialysis, the 12- and 24-
month dialysis initiation free rate was assessed as primary
endpoints between the pair-matched AST-120-treated and
non-AST-120treatedgroups.The3-,5-,and10-yearsurvival
rate after administration of AST-120 was assessed as a
secondary endpoint.
2.2. Evaluation. The background clinical data and concomi-
tant drugs of the two groups were compared using the chi-
square test. Age and other biochemical parameters were
expressed as mean ± SD, and statistical diﬀerences were
calculated by Student’s t-test. The level of urinary protein
excretion was expressed as median and tested by Mann-
Whitney’s U-test. Cumulative dialysis initiation free rate and
survival rate were plotted by the Kaplan-Meier method, and
intergroup diﬀerences were tested by the log-rank test. A
P value of less than 0.05 was considered signiﬁcant. Cox
regression adjusted for these factors was also performed. All
analyses were performed using SPSS (SPSS Inc, ver. 12.0,
Chicago, IL, USA).
3. Results
The baseline characteristics of the matched patients are
summarized in Table 2. After matching, no signiﬁcant dif-
ferences were observed in patients’ background between the
two groups. At the time of dialysis initiation, the eﬀect
of AST-120 on blood pressure, blood, and serum data
were compared between AST-120 and non-AST-120 group
(Table 3). There was no diﬀerence in blood and serum data
but systolic and diastolic blood pressure showed signiﬁcant
diﬀerence between two groups (P = 0.0217 and P = 0.0180,
resp.)
The eﬀect of AST-120 on dialysis initiation in the pair-
matched patients is shown in Figure 1. The 12- and 24-
month dialysis initiation free rate was signiﬁcantly higher
in the AST-120 group (25.0% and 13.7%, resp.) than in
the non-AST-120 group (10.5% and 5.7%, resp.) (Figure 1,
Table 4).
Using subgroup analysis, we evaluated the eﬃcacy of
AST-120 in patients with diabetic nephropathy or nondia-
betic renal disease, and also with or without cardiovascular
disease. For patients with diabetic nephropathy or cardiovas-
cular disease, the 12- and 24-month dialysis initiation free
ratewassigniﬁcantlyhigherintheAST-120groupthaninthe
non-AST-120 group(Figure 2,Table 4).This delayin dialysis
initiation was longer in patients with cardiovascular disease
or those without diabetic nephropathy.
We performed a Cox’s proportional hazard model based
on uni- and multivariate analysis to determine the inde-
pendent factors for dialysis initiation in the pair-matched
patients. For univariate analysis we selected eGFR and notInternational Journal of Nephrology 3
Table 1: Dialysis initiation criteria in Japan. According to the guidelines for introducing patients to dialysis issued by the Ministry of Health,
Labour and Welfare of Japan, sum total of 60 or higher is indication for dialysis initiation.
Items Score
Fluid retention
Electrolyte abnormality
Gastrointestinal symptoms
Circulatory symptoms
Clinical symptoms Neurological symptoms
Hematological disorders
Vision disorders
High grade 30
Intermediate grade 20
Low grade 10
serum creatinine (mg/d)
(creatinine clearance:CCr (mL/min))
Remnant Renal function sCr 8mg/mL or higher (CCr <10mL/min) 30
sCr 5∼8mg/mL(CCr10∼20mL/min) 20
sCr 3∼5mg/mL(CCr20∼30mL/min) 10
High grade: impossible to wake-up 30
Impairment level of daily living Intermediate grade: marked limitation of activity 20
Low grade: slight limitation of activity 10
Age 10 years or less 10
65 years or older 10
Systemic vascular disorder Existence of systemic vascular disorder 10
Table 2: Characteristics of 560 pair-matched patients. No signiﬁcant diﬀerences were observed in the backgrounds of the two groups. CKD:
chronic kidney disease, BMI: body mass index, Hb: hemoglobin, eGFR: estimated glomerular ﬁltration rate, Alb: albumin, IP: inorganic
phosphate, Ca: calcium, IP: inorganic phosphorus, BP: blood pressure, CVD: cardiovascular disease, DM: diabetes mellitus, Vit D: vitamin
D, ACEIs: angiotensin-converting enzyme inhibitors, ARBs: angiotensin receptor blockers.
All non-AST-120 AST-120 P value
n 560 280 280
Age 66.2 ±12.36 6 .4 ±12.06 6 .1 ±12.6 0.7869
Gender (M/F) 345/215 181/99 164/116 0.1396
CKD stage, n (%)
3 4 (0.7) 3 (1.1) 1 (0.4)
4 19 (3.4) 14 (5.0) 15 (5.3) 0.5956
5 527 (94.0) 263 (93.9) 264 (94.3)
Baseline data
BMI 23.7 ±4.12 3 .7 ±4.22 3 .7 ±4.0 0.8642
Hb (g/dL) 8.8 ±1.78 .9 ±1.88 .8 ±1.6 0.6265
eGFR (mL/min) 8.0 ±5.78 .0 ±6.98 .0 ±4.2 0.8847
Alb (g/dL) 3.6 ±0.63 .6 ±0.63 .6 ±0.6 0.9107
IP (mg/dL) 5.4 ±1.55 .4 ±1.65 .5 ±1.5 0.8662
Corrected Ca (mg/dL) 8.4 ±1.18 .4 ±1.08 .4 ±1.1 0.9841
Systolic BP (mmHg) 160 ±27.3 160 ±27.7 159 ±27.0 0.706
CVD (−/+), n 289/271 144/136 145/135 0.9326
DM (−/+), n 282/278 137/143 145/135 0.4989
Use of activated Vit D (−/+), n 172/388 88/192 84/196 0.714
Use of ACEls/ARBs (−/+), n 182/378 92/188 90/190 0.8568
Use of Ca Blocker (−/+), n 73/478 36/244 37/243 0.9001
Urine protein (mg/dL) (median) 264 200 270 0.28424 International Journal of Nephrology
Table 3: The eﬀect of AST-120 on blood pressure, blood, and serum data at the time of dialysis initiation.
At the time of HD initiation All non AST-120 AST-120 P value
Hb (g/L) 8.6 ±1.58 .5 ±1.68 .7 ±1.5 0.1276
BUN (mg/dL) 96.6 ±29.99 4 .4 ±28.69 8 .6 ±31.1 0.1786
Serum creatinine (mg/dL) 8.7 ±4.88 .4 ±2.89 .0 ±6.1 0.1702
IP (mg/dL) 6.2 ±1.66 .1 ±1.66 .3 ±1.6 0.4590
Total protein (g/dL) 6.1 ±0.86 .1 ±0.96 .1 ±0.8 0.6722
Albumin (g/dL) 3.4 ±0.63 .4 ±0.63 .4 ±0.6 0.5151
Corrected Ca (mg/dL) 8.5 ±1.18 .5 ±1.18 .6 ±1.1 0.6528
Systolic BP (mmHg) 162 ±25.5 165 ±26.5 159 ±24.2 0.0217
Diastolic BP (mmHg) 83.2 ±13.88 5 .0 ±14.18 1 .5 ±13.3 0.0180
Table 4: The 12- and 24-month dialysis initiation free rate. The dialysis initiation free rate was signiﬁcantly higher in the AST-120 group in
all the pair-matched patients and also subgroups with or without DM or CVD.
Dialysis initiation free rate (%) 12 months 24 months P value
AST-120 25.0 13.7 <0.0001
non-AST-120 10.5 5.7
AST-120, DM(−) 30.1 17.6 <0.0001
non-AST-120, DM(−) 11.2 8.2
AST-120, DM(+) 20.8 10.0 0.0057
non-AST-120, DM(+) 10.8 3.6
AST-120, CVD(−) 24.2 22.6
non-AST-120, CVD(−) 11.2 8.4 0.0063
AST-120, CVD(+) 27.2 12.8
non-AST-120, CVD(+) 9.8 2.9 <0.0001
Table 5: Uni- and multivariate analyses of the delaying eﬀect of AST-120 on dialysis initiation. Uni- and multivariate analyses showed
anemic status, eGFR, and not receiving AST-120 medication as independent factors associated with a signiﬁcant increase in risk of dialysis
initiation.
Univariate analysis P value Hazard ratio 95% CI
Age, <66.2, versus ≥66.2 0.808 0.979 0.828–1.158
CVD, without versus with 0.883 1.013 0.828–1.158
DM, without versus with 0.918 1.009 0.854–1.191
Systolic BP, <140, versus ≥140 0.228 1.123 0.930–1.355
BMI, <22, versus ≥22 0.960 1.004 0.846–1.193
ACEls/ARBs, without versus with 0.778 1.026 0.859–1.225
Ca blocker, without versus with 0.414 0.902 0.705–1.155
Activated Vit-D, without versus with 0.725 0.968 0.809–1.159
Hb, <8.8, versus ≥8.8 0.064 0.853 0.721–1.010
Alb, <3.6 versus, ≥3.6 0.996 1.000 0.846–1.183
Corrected Ca, <8.4 versus ≥8.4 0.681 1.036 0.875–1.227
Urine protein (mg/dL) 0.087 1.000 1.000–1.001
Urine protein (g/day) 0.488 1.001 0.999–1.003
eGFR, <8.0, versus ≥8.0 0.007 0.784 0.657−0.937
AST-120, with versus without 0.000 1.812 1.530–2.145
Multivariate analysis
Hb, <8.8, versus ≥8.8 0.042 0.837 0.705–0.994
eGFR, <8.0, versus ≥8.0 0.005 0.773 0.645–0.925
AST-120, with versus without 0.000 1.881 1.586–2.231International Journal of Nephrology 5
Table 6:The3-,5-,and10-yearsurvivalrateofpair-matchedpatients.The3-,5-,and10-yearsurvivalratesfromadministrationofAST-120
were analyzed by the Kaplan-Meier method with a log-rank test. Survival rates at 3-, 5-, and 10-years were not signiﬁcantly diﬀerent in the
AST-120 and non-AST-120 groups.
Survival 3-year 5-year 10-year P value
AST-120 79.0 63.8 29.8 0.0664
non-AST-120 78.1 65.6 44.0
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Figure 1: The delaying eﬀect of AST-120 on dialysis initiation. The
cumulative percentage of nondialysis patients analyzed by Kaplan-
Meier methods showed the delaying eﬀect of AST-120. The dialysis
initiation free rate was signiﬁcantly higher in the pair matched
patients receiving AST-120 (AST-120 group, n = 280) compared
to those not receiving AST-120 (non-AST-120 group, n = 280)
(P<0.001).
receiving AST-120 as independent factors for increasing the
risk for dialysis initiation. Similarly, for multivariate analysis
we selected anemic status, eGFR, and not receiving AST-120
as independent factors associated with a signiﬁcant increase
in risk of dialysis initiation (Table 5).
To examine whether or not the use of AST-120 in the
predialysis period inﬂuenced prognosis after dialysis initia-
tion, we compared the 3-, 5-, and 10-year survival rate from
administration of AST-120 by the Kaplan-Meier method
with a log-rank test. We found that there was no signiﬁcant
diﬀerence in survival rates between the AST-120 and non-
AST-120 groups (P = 0.0664) (Table 6, Figure 3).
4. Discussion
CKD is recognized as a disease that increases the risk of
many adverse events closely associated with death, such as
cardiovascular disease [15]. Early diagnosis and treatment
are necessary to delay CKD and prevent these adverse events.
AST-120 is an oral adsorbent that slows the progression of
CKD by decreasing serum nephrotoxic substances such as
indoxyl sulfate. Recently, the CAP-KD study was conducted
to evaluate the usefulness of AST-120 in patients with
moderate to severe CKD [16]. This study showed no
signiﬁcant diﬀerence in the composite primary endpoints
(doubling of sCr level, increase in sCr level ≥ 6.0mg/dL,
need for dialysis or transplantation, and death), but revealed
a signiﬁcant suppression in the decrease of estimated GFR
over56weeksintheAST-120group.However,becauseofthe
short follow-up period, the CAP-KD study could not clarify
theimpactofAST-120onthedevelopmentofend-stagerenal
disease [16].
In the present study, we retrospectively analyzed the
eﬀects of AST-120 to delay dialysis initiation and survival
in the context of current treatment regimens. Our results
showed a signiﬁcantly lower rate of dialysis initiation in
the AST-120 group. This indicated that AST-120 is a useful
treatment and supports recent retrospective studies by Ueda
et al. [8] and Maeda et al. [9] that also showed AST-120
delayed dialysis initiation. Furthermore, Maeda et al. [17]
reported long-term treatment of chronic renal failure with
AST-120 from early CKD stage has potential to slowing
progressionofrenalfailureanddelayinginitiationofdialysis.
In this present study, our result has limitation because main
patients were at the late stage of CKD (CKD stage 5) and
half of patients are initiated to hemodialysis within half year.
TheseresultssuggestthatAST-120administrationfromearly
CKD stage has potential to improve the progression of renal
failure eﬀectively.
The present study had some limitations. Although the
pair-matching method minimizes imbalances in patient
background, the ﬁnding that AST-120 delayed dialysis
initiation is not deﬁnitive, given that this was a retrospective
study on a relatively small number of patients from a single
institute. It is possible that the better outcomes in the AST-
120 group may be due to selection bias, and therefore a
prospective, randomized trial with long-term followup is
essentialtoevaluatetheeﬀectivenessofAST-120.Inaddition,
we could not evaluate the eﬀects of AST-120 on blood
and serum data from AST-120 administration to dialysis
initiation. Our data showed signiﬁcant decrease in blood
pressures at the time of dialysis initiation, but we could not
conclude the eﬀect of AST-120 on blood pressures because
of retrospective limitations. Recently, Nakamura et al. [18]
published AST-120 eﬀects on sCr, eGFR, serum interleukin-
6 (IL-6), proteinuria, and urinary excretion levels of 8-
hydoxydeoxyguanosine (8-OHdG) and L-fatty acid binding
protein (L-FABP), markers of oxidative stress and tubular
injury. In their prospective study, 50 patients were divided
in to 2 groups (AST-120 and non-AST-120 group, n = 25
each) and followed up for 12 months. They showed AST-120
treatment signiﬁcantly reduced sCr, eGFR, IL-6, proteinuria
8-OHdG, and L-FABP, but no eﬀect on blood pressure. This6 International Journal of Nephrology
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Figure 2:SubgroupanalysisofthedelayingeﬀectofAST-120ondialysisinitiation.Thecumulativepercentages ofnon-dialysispatientswere
analyzed by Kaplan-Meier methods. The dialysis initiation free rate was signiﬁcantly higher in the AST-120 group than in the non-AST-120
group in all subgroups, with DM [11] (a) or without DM (b), and with CVD (c) or without CVD (d).
study suggests AST-120 has potential to protect kidney from
stresses and injury.
In addition to its known eﬀect of delaying dialysis
initiation, the inﬂuence of AST-120 on subsequent prognosis
requires further study. Recent studies suggested that high
levels of serum indoxyl sulfate, one of the substances known
to enhance progression of atherosclerotic lesions, increase
the risk of a cardiovascular event or death in dialysis patients
[19].Thesestudiesshowedanassociationbetweentheserum
levels of indoxyl sulfate and mortality in CKD patients,
indicating that this nephrotoxic compound may be involved
in CKD progression and vascular disease [19]. Ueda et al.
[10]suggestedthatpatientsreceivingAST-120beforedialysis
initiation tend to have an improved prognosis. In their
report, the 5-year survival rate was signiﬁcantly higher in
the AST-120 group (72.6% in the AST-120 group and 52.6%
in the non-AST-120 group). However, our results showed
no signiﬁcant diﬀerence in survival rates between the pair-
matched AST-120 and non-AST-120 groups. This conﬂict
result might be caused by the initial CKD stage diﬀerence
in AST-120 administration. In the present study, 94% of
patients were stage 5 (eGFR, 8.0 ± 5.7mL/min) but CKD
stage of study population in Ueda et al. [10] was stage 4
(average of eGFR, 24-25mL/min). Yu et al. [20] prospec-
tively investigated the role of indoxyl sulfate in endothelial
dysfunction in CKD stage 4 patients and reported that
AST-120 administration improved endothelial dysfunction
associatedwithadecreaseinindoxylsulfateandarestorationInternational Journal of Nephrology 7
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Figure 3: Patient survival rate after the administration of AST-
120. Patient survival rate was not signiﬁcantly diﬀerent in the pair-
matched patients with or without AST-120 treatment.
of antioxidant reserve. H. Shibahara and N. Shibahara
[21] reported AST-120 administration contributed to the
improvement of cardiac and renal function in moderate
CKDpatients(sCr,1.3–2.0mg/dL)intheirprospectivestudy.
In addition, Nakamura et al. [18] evaluated AST-120 eﬀects
for tubulardamage through the reduction of proteinuria and
oxidative stress generation in CKD stage 4 patients. From
these observations, we speculate that long-term AST-120
administration from early CKD stage might be essential to
improve patient survival after dialysis initiation. However,
this contradictory result suggests that multiple factors may
have a considerable impact on patient survival and also that
there may be diﬃculties with retrospective analysis of CKD
patients with heterogeneous backgrounds. Prospective trials
are therefore necessary to conﬁrm the beneﬁcial eﬀects of
AST-120 on patient survival after dialysis initiation.
5. Conclusions
Although the present study is retrospective and has some
limitations, our results support the evidence that AST-
120 treatment is associated with signiﬁcant delays in the
cumulative dialysis initiation rate. However, it has no eﬀect
onpatientsurvivalafterdialysisinitiation.Aprospectiveran-
domized study may be necessary to probe survival beneﬁt.
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